BioNTech’s share price has taken a beating, but the analysts who follow the German biotech most closely are refusing to blink. That divergence — a market pricing in failure and a research community still talking about triple-digit price targets — is the defining tension around the stock right now.
The trigger for the latest bout of selling was a preliminary readout from AHEAD-MERIT, a Phase II/III trial testing the mRNA candidate BNT113 alongside the antibody pembrolizumab as a first-line treatment for advanced, HPV16-positive head and neck cancer. At the first analysis point, the combination failed to demonstrate a statistically significant improvement in progression-free survival versus pembrolizumab alone — one of two co-primary endpoints, and the one the market had been watching most closely.
Shares shed 7.6% in Tuesday trading, closing at EUR 79.40. That widened the gap to the 52-week high of EUR 105.80 to 25%. The stock has since traded at EUR 80.25, roughly 24% below that peak.
The Second Endpoint Is the One That Counts
The setback stung all the more because it landed barely weeks after BioNTech had halted a Phase II study of another candidate, Autogene Cevumeran, as a monotherapy in patients with operated colorectal cancer. Two disappointments in quick succession is a lot for any pipeline to absorb.
Yet the program is far from dead. After reviewing the interim data, the independent data monitoring committee explicitly recommended that the trial continue, keeping the focus squarely on the second dual primary endpoint: overall survival. Under the pre-specified study design, a statistically significant survival benefit on its own would be enough to formally declare the study a success. BioNTech remains blinded to the data, so details such as the hazard ratio, median progression-free survival and the exact timing of the final analysis are being kept under wraps for now.
Evercore and Citi Stand Their Ground
Institutional observers have greeted the missed endpoint with considerably more nuance than the trading floor. Evercore ISI analyst Cory Kasimov reaffirmed his “Outperform” rating and a USD 130 price target, noting that the progression-free survival miss was not entirely unexpected given earlier study data. He pointed to more encouraging trends on overall survival and stressed that the stock’s trajectory will hinge largely on other advanced pipeline projects such as Pumitamig.
Citi was equally unmoved. The bank reiterated its “Buy” rating and USD 125 target, arguing that convincing overall survival data could still keep the development path for BNT113 intact. The reasoning is notable: even after a missed interim milestone, the clinical trial can still deliver a positive result on the overall survival endpoint.
Should investors sell immediately? Or is it worth buying BioNTech?
Bank of America Securities took a slightly more cautious tack. Analyst Tazeen Ahmad trimmed her price target to USD 114 from USD 122 on Friday but kept her “Buy” recommendation firmly in place. Other houses have opted for hold ratings, though a broad retreat from the name has yet to materialize.
Cash, Pipeline and the Psychology of Insider Selling
The gap between price targets north of USD 100 and where the stock actually trades lays bare the current dilemma. Short-term sellers, the bulls argue, are overlooking the fact that oncology development rarely moves in a straight line.
Sentiment was not helped by share sales from BioNTech chief executive Ugur Sahin. The transactions were executed under a pre-arranged trading plan set up under Rule 10b5-1, which had been established on June 3, 2026. In an already jittery market, such signals still exert a psychological drag — investors are demanding tangible wins and reacting badly to any delay.
What the company does have is time, a luxury few biotech peers can claim. As of June 30, 2026, cash, cash equivalents and securities holdings stood at around EUR 16.63 billion. With 14 oncology studies running as of the summer, the pipeline is broad enough to cushion setbacks on individual candidates.
A Different Kind of Company, a Different Kind of Patience
The transition from pandemic-era vaccine champion to fully fledged cancer immunotherapy player is proving a gruelling test. Tumor therapies obey entirely different rules than the rapid vaccine development of a public health crisis. Biological complexity cannot be shortcut by deep pockets or high expectations, and the latest clinical readout drives that reality home once again.
For investors with a position in BioNTech — or those considering one — the message is plain: the era of fast vaccine profits is over. The transformation into a full-scale oncology group demands staying power. The risk-reward picture has arguably improved meaningfully at these depressed levels, but the burden of proof now rests squarely on the clinical data still to come. The final verdict on BNT113 has yet to be written.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from October 14 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 14.
BioNTech: Buy or sell? Read more here...
